Mode
Text Size
Log in / Sign up
N/A N=306 Randomized Treatment

SToRytelling to Improve DiseasE Outcomes in GOut: The STRIDE-GO2 Study

Gout · Low Medication Adherence · Health Related Quality of Life

Enrolled (actual)
306
Serious AEs
0.0%
Results posted
Feb 2022
Primary outcome: Primary: Medication Adherence — 72.61; 70.12; 68.52; 69.33 percentage of days ULT was taken

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Gout Storytelling Video Intervention (Behavioral)
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Dec 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Medication Adherence
72.61; 70.12; 68.52; 69.33; 65.85; 67.32
SECONDARY
Gout Flares
0.74; 0.99
SECONDARY
Patient Satisfaction
62.16; 67.43
SECONDARY
Target Serum Urate
5.94; 5.72

Summary

The objective is to test the efficacy of a patient-centered, culturally relevant narrative intervention, or "storytelling," based on the solid conceptual foundation of the narrative communication theory and the constructs of the Health Belief Model (HBM) to improve medication adherence and outcomes in chronic diseases among African-Americans (AA), using gout as an example. Gout is a chronic disease associated with chronic symptoms and disability interrupted by intermittent acute flares, similar to Chronic Obstructive Pulmonary Disease (COPD) and Congestive Heart Failure (CHF) that leads to joint destruction if not treated appropriately. Due to the intermittently symptomatic nature of chronic conditions, patients often don't perceive disease severity and susceptibility to disease complications, and, therefore, may not balance the barriers and benefits to medication adherence. Storytelling in the patients' own voices has the power to directly and more effectively confront a patient's barriers to medication adherence, reinforce the benefits and provide useful cues to action. Storytelling promotes patient engagement when the patient identifies with the storyteller and can lead to a patient's recognition of the need to treat the condition and improve health outcomes, as shown by a meaningful improvement in blood pressure in a recent clinical trial in AAs with hypertension. The success of this project, combined with other published data, will represent a major step toward demonstrating the effectiveness of storytelling to improve medication adherence in chronic diseases and will address two VA research priority areas, i.e., health care disparities and health care delivery.

Eligibility Criteria

Inclusion Criteria

  • African American Veteran Patients with Gout currently on urate-lowering therapy (ULT; most commonly allopurinol) with either low ULT adherence, defined as an average medication possession ration (MPR) =0.80

Exclusion Criteria

  • participants who use pill-box for ULT medication use
  • participants who Opt-out for the research will not be contacted
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02741700). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search